An estimated 2,000 to 3,000 Gulf patients carry a PNH clone, but only about 400 are confirmed and just 150 to 250 reach complement-inhibitor therapy, the gap this model has to size precisely.
The funnel narrows sharply between clonal prevalence and confirmed diagnosis in the Gulf. Consanguinity rates of 25 to 50 percent across Saudi Arabia, UAE, and Qatar are estimated to elevate true PNH prevalence 20 to 30 percent above the global average, implying a regional pool of roughly 2,000 to 3,000 clinically significant PNH clones. The Saudi National Rare Disease Registry confirms only around 400 cases, a gap this model attributes to diagnostic capacity rather than measurement error: fewer than 15 laboratories across all six GCC states offer FLAER flow cytometry, the gold-standard PNH test, and secondary hospitals that fall back to CD55/CD59-only testing carry a 20 to 30 percent false-negative rate for small clones. An estimated 40 to 50 percent of the true PNH population goes undiagnosed for more than three years, with median time to diagnosis for symptomatic patients running 2 to 4 years from first presentation.
Of the roughly 400 confirmed patients, an estimated 150 to 250 are on active complement-inhibitor therapy, with a broader treated-plus-undertreated population of 500 to 800 once informal and lapsed treatment is counted. Within that treated population, 40 to 80 patients remain transfusion-dependent despite anti-C5 therapy, extravascular haemolysis the anti-C5 class does not resolve. That population concentrates almost entirely at seven institutions across three cities: King Faisal Specialist Hospital and Research Centre in Riyadh, the region's largest published cohort at roughly 40 patients, King Abdulaziz Medical City in Riyadh and Jeddah, American Hospital Dubai, Rashid Hospital in Dubai, Sheikh Shakhbout Medical City in Abu Dhabi, and AUH in Abu Dhabi, managed by fewer than 10 haematologists in total, of whom only 5 to 8 function as genuine adoption gatekeepers for a new complement inhibitor.
GCC PNH funnel — from clonal prevalence to the treated, EVH-transfusing pool
| Funnel Stage | Population | Source |
|---|---|---|
| Estimated Gulf PNH clonal prevalence | 2,000–3,000 | Consanguinity-adjusted GCC epidemiology estimate (Al-Jishi et al., Saudi Med J 2020; GCC diagnostic network survey 2021) |
| Registry-confirmed PNH diagnoses | ~400 | Saudi National Rare Disease Registry (SNRHD), 2022 annual report |
| On active complement-inhibitor therapy | 150–250 | GCC haematology society PNH case registry; KFSH&RC published case series |
| Transfusion-dependent despite anti-C5 therapy (EVH) | 40–80 | GCC haematology society PNH case registry |
Sources: Saudi National Rare Disease Registry (SNRHD) 2022 annual report; Al-Jishi EA et al., Saudi Med J 2020; GCC rare disease diagnostic network survey 2021; Tarawah A et al., Hematol Oncol Stem Cell Ther 2019; KFSH&RC haematology department published case series 2019-2023; GCC haematology society PNH case registry; AXLRx disease-landscape and launch-readiness research.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The ~400-patient SNRHD registry count against the 2,000-to-3,000-patient consanguinity-adjusted epidemiology estimate
- why the gap is a diagnostic-capacity constraint, not a measurement error
Delivers
- The 150-to-250-patient treated population and 500-to-800-patient treated-plus-undertreated pool
- the 40-to-80-patient EVH-transfusing cohort concentrated across seven named referral institutions
Delivers
- 8-sheet structure mirroring the standard AXLRx patient flow architecture
- SNRHD, NPHC, and published GCC epidemiology-literature citation per conversion step
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why diagnostic capacity, not drug access, sets the addressable pool across six GCC states
- Pressure-tested against the SNRHD-versus-epidemiology reconciliation before the rest of the model is built out
- 2,000-3,000 estimated Gulf PNH patients, consanguinity-adjusted 20-30% above global average
- 25-50% consanguinity rates across Saudi Arabia, UAE, and Qatar as the primary prevalence driver
- ~400 confirmed cases in the Saudi National Rare Disease Registry (SNRHD)
- Fewer than 15 FLAER-capable labs across six GCC states; 40-50% of patients undiagnosed beyond three years
- 150-250 patients on active complement-inhibitor therapy; 500-800 treated-plus-undertreated
- 40-80 patients transfusion-dependent despite anti-C5 therapy (EVH)
- NPHC coverage of eculizumab/ravulizumab under FLAER clone ≥10% plus LDH ≥2x ULN criteria
- Iptacopan's SFDA Priority Review pathway and the GCC registration lag behind FDA/EMA
- Diagnostic capacity ranked ahead of prevalence rate as the assumption most likely to move the addressable pool
- Scenario ranges across the SNRHD-registry and consanguinity-adjusted estimates
- Patient volume by horizon under conservative, base, and aggressive uptake scenarios
- Revenue translation inputs
- The open questions your forecasting team must close before the model is finalised
- Structured for an internal forecast-review session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx patient flow model is built on a five-layer funnel: population, disease burden (E1), diagnosis and specialist capture (E2), treatment and biomarker eligibility (E3), market access (E4), then Year 1-3-5 projections across three scenarios. Delivered as a live Excel workbook, not a static table, across 8 sheets with zero hardcoded cells.
GCC PNH sources: Saudi National Rare Disease Registry (SNRHD) annual reporting, published GCC consanguinity-rate and prevalence literature, the GCC rare disease diagnostic network survey, and KFSH&RC and GCC haematology society case-registry data.
- GCC clonal prevalence estimate verified against published consanguinity-rate and rare-disease prevalence literature (Al-Jishi et al., Saudi Med J 2020)
- Registry-confirmed diagnosis count verified against the Saudi National Rare Disease Registry (SNRHD) 2022 annual report
- Diagnostic capacity constraint (FLAER lab count, undiagnosed share) verified against the GCC rare disease diagnostic network survey 2021
- Treated and EVH-transfusing population sizes verified against the GCC haematology society PNH case registry and KFSH&RC published case series
Frequently asked questions
Commission this model
AXLRx delivers rare disease patient flow models built for forecasting and launch teams sizing the GCC PNH opportunity. Custom model in 72 hours.
Specify your indication, market, and cohort definition.
AXLRx analyst confirms funnel scope and comparator set before building.
Research-verified patient flow model in 72 hours with optional analyst readout.